A federal judge on Wednesday blocked Colorado ​from capping the price of Amgen's blockbuster arthrit

AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier

Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified wa

CNBC Final trades: Lebenthal picks Micron, Snipe chooses Palo Alto, Brown expects Apple's good s

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth expl

Cisco Systems is on a roll with its AI-powered platform. Coca-Cola saw volume growth in each of its

The New England Journal of Medicine on Monday retracted an article on a pivotal clinical trial that

Shares of Quantinuum slide after rallying since IPO. Analysts weigh in.

The U.S. Food and Drug Administration on Friday approved Viridian Therapeutics Inc.'s (NASDAQ:VRDN)

FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch

The committee is recommending that no new patients start treatment with Tavneos and that existing pa

The European Medicines Agency on ‌Friday recommended revoking the marketing authorisation for Amgen'

As millions take GLP-1 drugs, packaged food giants face declining volumes while protein brands and s

Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics

Mizuho analyst Salim Syed maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price targe

Morgan Stanley analyst Terence Flynn maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises

Approval Based Upon Phase 3 DeLLphi-304 Trial Demonstrating 40% Reduction in Risk of Death with IMDY

Ember LifeSciences, Inc., ("Ember") a leading provider of revolutionary cold chain technolog

Amgen partner Kissei advised doctors to avoid new Tavneos use in Japan after FDA liver injury warnin

https://www.wsj.com/health/pharma/20-people-in-japan-died-after-taking-amgen-drug-40edaefd?mod=Searc

Piper Sandler analyst David Amsellem maintains Amgen (NASDAQ:AMGN) with a Overweight and lowers t

U.S. officials discussed possible SSRI restrictions as RFK Jr. unveiled a broader push to reduce ant

Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and lowers the price

Amgen (NASDAQ: AMGN) today announced plans to invest an additional $300 million in its U.S. manufact

Truist Securities analyst Gregory Renza maintains Amgen (NASDAQ:AMGN) with a Hold and raises the

U.S. stocks hit fresh records as Apple's blowout Q2 powered Big Tech, while crude oil sank 3% on

Amgen (NASDAQ:AMGN) raises FY2026 Adj EPS guidance from $21.60-$23.00 to $21.70-$23.10 vs $22.33 ana

Amgen (NASDAQ:AMGN) raises FY2026 GAAP EPS guidance from $15.45-$16.94 to $15.62-$17.10 vs $15.18 an

Amgen (NASDAQ:AMGN) reported quarterly earnings of $5.15 per share which beat the analyst consensus

A sharp rotation gripped Wall Street at midday Thursday as blue-chip industrials and healthcare powe

Sen. Warren challenges Trump's 600% TrumpRx drug price claim using a glass of water.

FDA unit proposes Amgen's Tavneos withdrawal citing manipulated trial data, lack of efficacy evi

https://www.fda.gov/media/192160/download?attachment

It's a big week for the Dow Jones Industrial Average with 11 of the 30 components reporting earn

A member of Congress recently bought hundreds of thousands of dollars in stocks, marking her first t

Canaccord Genuity analyst Gary Nachman initiates coverage on Amgen (NASDAQ:AMGN) with a Hold rati

https://www.aboutamazon.com/news/retail/amazon-glp1-management-program

Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price

Cantor Fitzgerald analyst Carter Gould reiterates Amgen (NASDAQ:AMGN) with a Neutral and maintain

Viridian shares fall after Amgen TEPEZZA Phase 3 data shows stronger efficacy, raising concerns over

Amgen shares fall despite Phase 3 TEPEZZA OBI data showing 77% response rate and proptosis reduction

Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (tepro

According to a Bloomberg report, Trump may impose 100% tariffs on drugmakers without pricing deals,